<DOC>
	<DOCNO>NCT01236586</DOCNO>
	<brief_summary>Background : - The anti-cancer drug RO4929097 test ability block blood vessel growth tumor slow stop growth cancer cell . However , use small number adult yet test child . Researchers interested determine whether RO4929097 safe effective treatment tumor leukemia responded standard treatment . Objectives : - To determine safety effectiveness RO4929097 treatment child adolescent diagnose certain kind cancer respond standard treatment . Eligibility : - Children , adolescent , young adult 1 21 year age diagnose solid , nervous system , blood-based cancer respond standard treatment . Design : - Participants screen medical history , physical examination , blood urine test , image study . Some participant may also bone marrow biopsy evaluate state disease . - Participants separate three group : One group receive RO4929097 alone , two receive RO4929097 combination immune-suppressing drug dexamethasone . - RO4929097 give tablet one two schedule : day 1 3 every week ( Schedule A ) day 1 5 every week ( Schedule B ) . The dosing schedule determine randomly . Every 4-week treatment period one cycle , participant may receive RO4929097 24 cycle . - Participants frequent blood urine test image study evaluate progress treatment , ask keep diary monitor side effect .</brief_summary>
	<brief_title>RO4929097 Children With Relapsed/Refractory Solid CNS Tumors , Lymphoma , T-Cell Leukemia</brief_title>
	<detailed_description>Background : - Notch signal aberrantly activate variety human tumor include solid tumor hematological malignancy include T-cell leukemia ( T-ALL ) pediatric cancer , osteosarcoma , glioma , medulloblastomas , ependymoma , hematological malignancy . - One emerge strategy inhibit Notch signaling use gamma-secretase inhibitor ( GSIs ) , prevent Notch receptor activation cleavage . - RO4929097 orally administer small molecule potent selective GSI , show antitumor activity preclinical study . Objectives : - To determine maximum tolerate dose ( MTD ) recommend Phase 2 dose , associate toxicity RO4929097 administer orally child relapsed/refractory solid tumor lymphoma 2 schedule : daily orally 3 day on/4 day weekly schedule ( schedule A ) daily 5 consecutive day weekly schedule ( schedule B ) . - To determine MTD recommend Phase 2 dose , associate toxicity RO4929097 administer dexamethasone . - To characterize pharmacokinetics RO4929097 child refractory cancer . - To preliminarily define anti-tumor activity RO4929097 child refractory solid tumor within confines phase I study . - To determine initial efficacy anti-tumor activity RO4929097 combine dexamethasone child relapsed/refractory T-ALL . - To study effect RO4929097 component Notch signal pathway peripheral blood mononuclear cell and/or T-ALL blast , examine archival tumor sample expression amplification target molecule , preliminarily assess change treatment use FDG PET image . Eligibility : - Patients great 12 month less equal 21 year age diagnosis histologic verification ( except patient intrinsic brain stem tumor , optic pathway glioma ) measureable evaluable relapsed refractory disease . Current disease state must one know curative therapy , therapy proven prolong survival acceptable quality life . - Subjects must able swallow tablet . - Patients pregnant , know serologically positive Hepatitis A , B , C , history liver disease , prolong QTc eligible . Design : - This phase I study first evaluate safety pharmacokinetics RO4929097 administer orally child relapsed/refractory solid tumor ( Part 1 ) 2 schedule : daily 3 day on/4 day weekly schedule ( Schedule A ) daily 5 consecutive day weekly schedule ( Schedule B ) . - One cycle 28 day , subject may continue cycle absence progressive disease unacceptable treatment-related toxicity total 24 cycle . - After determine MTD RO4929097 , evaluation RO4929097 plus concomitant dexamethasone ( Part 2 ) least one schedule test Part 1 , undertake . - After MTD RO4929097 plus dexamethasone identify , enrollment subject relapsed/refractory T-ALL ( Part 3 ) undertaken obtain initial efficacy data patient population .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<criteria>ELIGIBILITY CRITERIA : Patients great 12 month less equal 21 year age diagnosis histologic verification ( except patient intrinsic brain stem tumor , optic pathway glioma ) measureable evaluable relapsed refractory disease . Current disease state must one know curative therapy , therapy proven prolong survival acceptable quality life . Subjects must able swallow tablet . Patients pregnant , know serologically positive Hepatitis A , B , C , history liver disease , prolong QTc eligible .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 13, 2011</verification_date>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>NOTCH Signaling Pathway</keyword>
	<keyword>Expression JAGGED 1 2</keyword>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Wilms Tumor</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Lymphoma</keyword>
</DOC>